Get the Stockscreener App
0.131
5.21%
-0.0072
After Hours:
.13
-0.001
-0.76%
Zomedica Corp stock is traded at $0.131, with a volume of 5.52M.
It is down -5.21% in the last 24 hours and up +5.22% over the past month.
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
See More
Previous Close:
$0.1382
Open:
$0.1368
24h Volume:
5.52M
Relative Volume:
0.87
Market Cap:
$128.37M
Revenue:
$25.19M
Net Income/Loss:
$-34.53M
P/E Ratio:
-3.6389
EPS:
-0.036
Net Cash Flow:
$-20.62M
1W Performance:
-10.82%
1M Performance:
+5.22%
6M Performance:
-9.41%
1Y Performance:
-18.38%
1-Day Range:
$0.1301
$0.1379
1-Week Range:
$0.1301
$0.1533
52-Week Range:
$0.117
$0.1952
Zomedica Corp Stock (ZOM) Company Profile
Name
Zomedica Corp
Sector
Phone
734-369-2555
Address
100 Phoenix Drive, Suite 190, Ann Arbor, MI
Compare ZOM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZOM
Zomedica Corp
|
0.131 | 128.37M | 25.19M | -34.53M | -20.62M | -0.036 |
|
ZTS
Zoetis Inc
|
163.32 | 73.68B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.10 | 41.15B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.95 | 41.06B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.94 | 23.73B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
140.90 | 14.27B | 2.24B | 385.90M | 440.10M | 3.73 |
Zomedica Corp Stock (ZOM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-23 | Initiated | Dawson James | Buy |
Zomedica Corp Stock (ZOM) Latest News
Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 2.2% – Here’s What Happened - Defense World
Geode Capital Management LLC Buys 321,395 Shares of Zomedica Corp. (NYSEAMERICAN:ZOM) - Defense World
Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 2.2% – Here’s Why - Defense World
Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 2.2%What's Next? - MarketBeat
Zomedica enters license and supply agreement with Cresilon Inc. - DVM 360
Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market - AccessWire
Zomedica Secures Exclusive U.S. Rights to Revolutionary Vetigel Bleeding Control Technology - StockTitan
Zomedica Unveils New Canine Tests Offering Faster Diagnostics for Heart and Breeding Health - AOL
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone - AccessWire
Zomedica Expands TRUFORMA Platform with Breakthrough 20-Minute Cardiac and Breeding Diagnostic Tests - StockTitan
Zomedica appoints Scott Jordan as EVP, finance & CFO - MSN
Zomedica (NYSEAMERICAN:ZOM) Trading Down 2.8% – Here’s Why - Defense World
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer - AccessWire
Zomedica Strengthens Leadership: Industry Veteran with 30+ Years Experience Named New CFO - StockTitan
Zomedica (NYSEAMERICAN:ZOM) Trading Down 2.8%Should You Sell? - MarketBeat
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024 - AccessWire
Zomedica CEO to Present at NobleCon20 Conference, Investor Meetings Scheduled - StockTitan
Zomedica secures new lease for headquarters expansion By Investing.com - Investing.com South Africa
Zomedica secures new lease for headquarters expansion - Investing.com
Noble Financial Predicts Zomedica FY2024 Earnings - MarketBeat
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform - AccessWire
Zomedica Launches 18-Minute Equine Insulin Test, Expands TRUFORMA Platform Capabilities | ZOM Stock News - StockTitan
Johnny D. Powers Purchases 100,000 Shares of Zomedica Corp. (NYSEAMERICAN:ZOM) Stock - MarketBeat
Zomedica (NYSEAMERICAN:ZOM) Stock Rating Upgraded by Noble Financial - MarketBeat
Noble Capital Markets Initiates Equity Research Coverage on Zomedica - WICZ
Zomedica (ZOM) Launches Noble Capital Markets Coverage to Boost Market Visibility | ZOM Stock News - StockTitan
Zomedica initiated with an Outperform at Noble Capital - TipRanks
Zomedica Corp. (AMEX:ZOM) Q3 2024 Earnings Call Transcript - Insider Monkey
Zomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... By GuruFocus - Investing.com Canada
Earnings call: Zomedica reports record Q3 revenue, eyes future growth By Investing.com - Investing.com Australia
Zomedica stock plunges to 52-week low of $0.12 amid market challenges By Investing.com - Investing.com South Africa
Earnings call: Zomedica reports record Q3 revenue, eyes future growth - Investing.com
Zomedica’s Revenue Up 10% Amid Global Expansion - TipRanks
Zomedica stock plunges to 52-week low of $0.12 amid market challenges - Investing.com India
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024 - Herald Palladium
Zomedica CEO to Present at Sidoti Micro Cap Conference, Showcases Pet Health Innovation | ZOM Stock News - StockTitan
Zomedica Corp Posts Increased Revenue Amid Loss - TipRanks
Zomedica Announces Third Quarter 2024 Financial Results: Revenue - WICZ
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth - AccessWire
Zomedica Q3 Revenue Jumps 10%, Diagnostics Surges 38% Despite Wider Losses | ZOM Stock News - StockTitan
Zomedica stock plunges to 52-week low at $0.12 amid market challenges - Investing.com India
ZOMZomedica Corp. Latest Stock News & Market Updates - StockTitan
Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform - AccessWire
Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET - AccessWire
Zomedica stock plunges to 52-week low at $0.12 amid market challenges By Investing.com - Investing.com South Africa
Adversity is less terrifying than hope: Zomedica Corp (ZOM) - SETE News
Zomedica Corp Stock (ZOM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):